Moss Genomics Announces Closing of Financing Round

About this update from Moss Genomics, Inc.

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") announces that, effective as of November 11, 2025, it has closed a non-brokered private placement of 555,555 common shares at $0.18 per share for gross proceeds of $100,000. No finder's fees were paid. Net proceeds will be used for general working capital.In addition, effective as of November 11, 2025, Moss issued an aggregate 5,164,213 common shares at a deemed price of $0.18 per share as consideration under asset purchase agreements entered into between May 13, 2025 and July 14, 2025, pursuant to which the Company acquired approximately 224.7523 ETH at an average price of $3,833 per ETH (aggregate deemed consideration $966,435).This announcement represents the official completion of the private placement and related share issuances first announced on February 3, 2025. Following completion of the foregoing transactions, Moss has 63,414,545 common shares issued and outstanding. All securities issued are subject to applicable statutory hold periods under Canadian securities laws.AGSM Scheduled for November 13, 2025Moss will hold its Annual and Special General Meeting on November 13, 2025, to be conducted virtually. Meeting time, access instructions, record date, and matters of business will be set out in the Company's meeting materials and have been posted on its website.About Moss Genomics Inc.Moss Genomics is developing a secure and user-controlled platform for genomic data, enabling individuals to vault their DNA, manage access permissions, and participate in research monetization opportunities. Moss is building on Ethereum-based infrastructure, with ETH used to fund development, DNA sequencing services, and future platform operations. The company's mission is to advance decentralized and privacy-preserving genomics through real-world applications in health, identity, and research. CONTACT INFORMATIONMoss Genomics Inc.Jack Liu, Chief Executive Officer and Director Email: [email protected]: 604-710-0124Cautionary Statement:The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.For...

View stock analysis, news, and events for Moss Genomics, Inc.